Best of the other journals

Yang TB et al. J Allergy Clin Immunol. 2019;144:353‐360 https ://doi.org/10.1016/j.jaci.2019.06.016 This is an exciting article addressing a common symptom of allergic disease(s)—itch. The authors discuss the currently understood im‐ muno‐pathogenesis and management of itch, highlighting how in‐ effective antihistamines are in combating itch, suggesting that the pathogenesis of itch encompasses both histaminergic (IgE‐mast cell‐ histamine axis) and non‐histaminergic pathways. Recent advances in the biology and neuroimmunology of itch have provided key new insight into the development of various new targeted therapies such as dupilumab, tralokinumab, lebrikizumab, neurokinin receptor an‐ tagonists, Mrgpr antagonists and JAK inhibitors, which are likely to transform the management of itch‐associated disorders in allergy and immunology.